66
Participants
Start Date
August 31, 2007
Primary Completion Date
August 31, 2011
Study Completion Date
June 15, 2015
Fludarabine, Melphalan +/- ATG
"Conditioning regimen for Allogenic Stem Cell Transplant:~Related Donor Fludarabine days -6 to -2 (30mg/m2 IVPB over 30 minutes daily) Melphalan days -3 to -2 (70mg/m2 IVPB over 30 minutes daily)~Unrelated Donor Fludarabine days -6 to -2 (30mg/m2 IVPB over 30 minutes daily) Melphalan days -3 to -2 (70mg/m2 IVPB over 30 minutes daily) ATG (Thymoglobulin®) days -3 to -1 (0.5 mg/kg IV on day -3 \[given over 6 hours\], and 2 mg/kg on days -2 and -1 \[given over 4 hours\])"
Icahn School of Medicine at Mount Sinai, New York
Weill Cornell Medical College, New York
Roswell Park Cancer Institute, Buffalo
Johns Hopkins, Baltimore
Ospedali Riuniti di Bergamo, Bergamo
Ohio State Univesity, Columbus
University of Florence, Florence
Regionala etikprovningsnamnden Goteborg, Gothenburg
University of Illinois at Chicago, Chicago
University of Utah, Salt Lake City
Princess Margaret Hospital, Toronto
University of San Martino, San Martino
National Institutes of Health (NIH)
NIH
Myeloproliferative Disorders-Research Consortium
NETWORK
National Cancer Institute (NCI)
NIH
John Mascarenhas
OTHER